Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Guardant Health, Inc. Common Stock

GH

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Last trade $144.56
Day change +$0.53 (+0.37%)
Day range $141.15 – $149.00
Volume 1,222,801
Market cap $19.49B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$19.49B
Price / earnings
—
Price / book
-70.62×
Price / sales
15.24×
EV / sales
15.61×
EV / EBITDA
-42.94×

Profitability

Earnings per share
-$3.59
Return on assets
-25.72%
Return on equity
175.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-5.45×
Current ratio
3.6×
Quick ratio
3.35×
Cash ratio
2.75×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$232.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GH, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$360.98M$334.98M$301.67M$281.27M$265.2M$232.09M$203.47M$201.81M
Cost of revenue$124.82M$115.95M$104.92M$99.49M$93.59M$81.21M$74.72M$77.59M
Gross profit$236.15M$219.03M$196.75M$181.77M$171.61M$150.88M$128.75M$124.22M
Selling, general and administrative$268.08M$251.61M$227.06M$204.32M$180.64M$169.85M$151.27M$156.64M
Research and development$100.84M$96.53M$91.04M$98.26M$89.96M$87.45M$88.52M$93.54M
Total operating expenses$368.92M$348.15M$318.1M$302.58M$270.6M$257.3M$239.79M$250.19M
Operating income-$132.77M-$129.12M-$121.35M-$120.81M-$98.99M-$106.41M-$111.04M-$125.97M
Interest expense-$1.35M-$1.35M-$1.35M-$1.18M-$943K-$983K-$791K-$645K
Income before taxes-$124.02M-$119.96M-$111.7M-$130.22M-$92.59M-$99.86M-$94.87M-$110.29M
Income taxes$343K$185K$372K-$1.73M$136K$38K$290K$716K
Net income-$124.36M-$120.14M-$112.08M-$128.49M-$92.73M-$99.9M-$95.16M-$111.01M
Net income attributable to common shareholders-$124.36M-$120.14M-$112.08M-$128.49M-$92.73M-$99.9M-$95.16M-$111.01M
EBITDA-$122.59M-$119.56M-$111.91M-$110.76M-$89.58M-$96.37M-$100.81M-$115.51M
Basic earnings per share-$0.93-$0.90-$0.85-$1.00-$0.74-$0.80-$0.77-$0.90
Diluted earnings per share-$0.93-$0.90-$0.85-$1.00-$0.74-$0.80-$0.77-$0.90

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

Guardant Health reported a quarterly loss of $0.29 per share, matching consensus estimates and improving from a $0.39 loss a year ago. The company exceeded revenue expectations with $360.98 million, up from $265.2 million year-over-year. The stock has gained 65.1% since the beginning of the year, significantly outperforming the S&P 500's 12.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Guardant Health reported Q3 2026 revenue of $360.98 million, beating Wall Street estimates by 2.89% with 36.1% year-over-year growth. The company posted an EPS of -$0.29, matching consensus estimates. Key metrics showed strong performance across screening tests (83,000 vs. 72,322 estimate) and oncology revenue (+25.4% YoY), though biopharma revenue slightly missed expectations. The stock holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The article explains how to use the Zacks Earnings ESP (Expected Surprise Prediction) filter to identify stocks likely to beat earnings expectations. The ESP compares the most accurate analyst estimate to the consensus estimate, and when combined with a Zacks Rank #3 or better, stocks posted positive surprises 70% of the time with average annual returns of 28%. Two medical stocks highlighted as examples are Humana (HUM) with a #2 Buy rating and +3.33% ESP, and Guardant Health (GH) with a #3 Hold rating and +4.76% ESP.

Zacks Investment Research

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Guardant Health is expected to report Q3 2026 earnings on November 5 with a consensus loss of $0.29 per share and revenues of $350.83 million (up 32.3% YoY). The company has a positive Earnings ESP of +4.76% combined with a Zacks Rank #3, suggesting it will likely beat consensus estimates. However, recent estimate revisions have been 6.86% lower over the last 30 days.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.